Carmen Massa

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy.

The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy.

Journal: Biochemistry and biophysics reports

Published: May 11, 2026

A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.

A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.

Journal: Gut microbes

Published: March 19, 2026

LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma.

LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma.

Journal: Biochemical pharmacology

Published: December 01, 2025

Harnessing the Estradienone Scaffold to Develop Dual GPBAR1 and LIFR Modulators for Liver Fibrosis.

Harnessing the Estradienone Scaffold to Develop Dual GPBAR1 and LIFR Modulators for Liver Fibrosis.

Journal: Journal of medicinal chemistry

Published: September 24, 2025

Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancer.

Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancer.

Journal: Translational oncology

Published: August 22, 2025

Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4-/- mice.

Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4-/- mice.

Journal: Hepatology communications

Published: February 26, 2025

Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis.

Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis.

Journal: Biochemical pharmacology

Published: February 07, 2025

Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis.

Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis.

Journal: Journal of medicinal chemistry

Published: October 09, 2024

Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism.

Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 20, 2024

Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice.

Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 06, 2024

Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases.

Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases.

Journal: Pharmacological research

Published: July 24, 2024

Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.

Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.

Journal: Biochemical pharmacology

Published: December 04, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026